Literature DB >> 16230503

Molecular basis of arrhythmias.

Manish Shah1, Fadi G Akar, Gordon F Tomaselli.   

Abstract

The characterization of single gene disorders has provided important insights into the molecular pathogenesis of cardiac arrhythmias. Primary electrical diseases including long-QT syndrome, short-QT syndrome, Brugada syndrome, and catecholaminergic polymorphic ventricular tachycardia have been associated with mutations in a variety of ion channel subunit genes that promote arrhythmogenesis. Pathological remodeling of ionic currents and network properties of the heart critical for normal electrical propagation plays a critical role in the initiation and maintenance of acquired arrhythmias. This review focuses on the molecular and cellular basis of electrical activity in the heart under normal and pathophysiological conditions to provide insights into the fundamental mechanisms of inherited and acquired cardiac arrhythmias. Improved understanding of the basic biology of cardiac arrhythmias holds the promise of identifying new molecular targets for the treatment of cardiac arrhythmias.

Entities:  

Mesh:

Year:  2005        PMID: 16230503     DOI: 10.1161/CIRCULATIONAHA.104.494476

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  57 in total

Review 1.  CaMKII, an emerging molecular driver for calcium homeostasis, arrhythmias, and cardiac dysfunction.

Authors:  Chad E Grueter; Roger J Colbran; Mark E Anderson
Journal:  J Mol Med (Berl)       Date:  2006-11-21       Impact factor: 4.599

Review 2.  Clinical genetics in cardiology.

Authors:  Philippe Charron
Journal:  Heart       Date:  2006-08       Impact factor: 5.994

Review 3.  Modification of K+ channel-drug interactions by ancillary subunits.

Authors:  Glenna C L Bett; Randall L Rasmusson
Journal:  J Physiol       Date:  2007-12-20       Impact factor: 5.182

Review 4.  Late sodium current in failing heart: friend or foe?

Authors:  Victor A Maltsev; Albertas Undrovinas
Journal:  Prog Biophys Mol Biol       Date:  2007-08-10       Impact factor: 3.667

5.  Re-evaluating the efficacy of beta-adrenergic agonists and antagonists in long QT-3 syndrome through computational modelling.

Authors:  Rebecca C Ahrens-Nicklas; Colleen E Clancy; David J Christini
Journal:  Cardiovasc Res       Date:  2009-03-05       Impact factor: 10.787

Review 6.  Identifying patients at high risk of a cardiovascular event in the near future: current status and future directions: report of a national heart, lung, and blood institute working group.

Authors:  Kim A Eagle; Geoffrey S Ginsburg; Kiran Musunuru; William C Aird; Robert S Balaban; Susan K Bennett; Roger S Blumenthal; Shaun R Coughlin; Karina W Davidson; Edward D Frohlich; Philip Greenland; Gail P Jarvik; Peter Libby; Carl J Pepine; Jeremy N Ruskin; Arthur E Stillman; Jennifer E Van Eyk; H Eser Tolunay; Cheryl L McDonald; Sidney C Smith
Journal:  Circulation       Date:  2010-03-30       Impact factor: 29.690

7.  Analysis of genetic and non-genetic factors that affect the QTc interval in a Mongolian population: the GENDISCAN study.

Authors:  Sun-Wha Im; Mi Kyeong Lee; Hee Jeong Lee; Se-Il Oh; Hyung-Lae Kim; Joohon Sung; Sung-Il Cho; Jeong-Sun Seo; Jong-Il Kim
Journal:  Exp Mol Med       Date:  2009-11-30       Impact factor: 8.718

8.  Successful acute and long-term management of electrical storm in Brugada syndrome using orciprenaline and quinine/quinidine.

Authors:  Patrick A Schweizer; Rüdiger Becker; Hugo A Katus; Dierk Thomas
Journal:  Clin Res Cardiol       Date:  2010-03-11       Impact factor: 5.460

9.  Adenylyl cyclase 6 deletion increases mortality during sustained β-adrenergic receptor stimulation.

Authors:  Tong Tang; N Chin Lai; Adam T Wright; Mei Hua Gao; Paul Lee; Tracy Guo; Ruoying Tang; Andrew D McCulloch; H Kirk Hammond
Journal:  J Mol Cell Cardiol       Date:  2013-04-12       Impact factor: 5.000

Review 10.  Late sodium current is a new therapeutic target to improve contractility and rhythm in failing heart.

Authors:  Albertas Undrovinas; Victor A Maltsev
Journal:  Cardiovasc Hematol Agents Med Chem       Date:  2008-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.